Plasma cfDNA Genotyping in Hospitalized Patients With Suspected Metastatic NSCLC.
Michael L ChengMarina S D MilanRubii M TamenArrien A BertramKesi S MichaelBiagio RicciutiKenneth L KehlMark M AwadLynette M ShollCloud P PaweletzPasi A JännePublished in: JCO precision oncology (2022)
Plasma cfDNA NGS before pathologic diagnosis in hospitalized patients with suspected metastatic NSCLC results in substantially shorter time to genotyping result compared with standard outpatient workflows. This provides important initial evidence for the use of plasma-based genotyping earlier in the diagnostic journey, especially for patients with clinically aggressive disease. Additional studies and innovative approaches toward regulatory and reimbursement considerations are needed.